Julia Kronberger

Julia Kronberger

Auto-generated profile, based on publicly available information

Julia Kronberger

Institute of Inorganic Chemistry, Faculty of Chemistry

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in ChemMedChem
Verified
Journal Article
Open access
XGXabier Guarrochena
Xabier Guarrochena
JKJulia Kronberger
Julia Kronberger
MTManuel Tieber
Manuel Tieber
PCPhilipp Ciesielski
Philipp Ciesielski
Thomas MindtThomas Mindt
Thomas Mindt
IFIrene V. J. Feiner
Irene V. J. Feiner
DFO* is an octadentate chelator able to form highly stable chelates with Zirconium‐89 (89Zr) for nuclear medicinal applications in Positron Emission Tomography (PET).[1,2] The synthesis of DFO* and its scale‐up remains challenging by reported synthetic protocols. For this reason, we set out to develop a de novo synthesis of a hydroxamate‐containing building block suitable for the coupling to the commercially available DFO (desferrioxamine B, mesylate salt) yielding, after deprotection, the desired chelator DFO* in a more efficient procedure. Highlights of the new synthesis of DFO* reported herein are less synthetic steps and the isolation of the desired product DFO* by using solid phase extraction (SPE), thus avoiding tedious HPLC purification. DFO* is obtained in excellent purity (92‐98 %) and an overall yield of approximately 29 %. In addition, the isolated trifluoroacetic acid (TFA)‐salt of DFO* displays an improved solubility in organic solvents (DMSO, DMF, methanol), which will facilitate its use for the preparation of structurally diverse derivatives suitable for bioconjugation chemistry and the development of 89Zr‐labeled radiotracers.

17 June 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JKJulia Kronberger
Julia Kronberger
TBTheresa Balber
Theresa Balber
HSHemma Schueffl
Hemma Schueffl
RWRaphaela Wahrmann
Raphaela Wahrmann
AFAnja Federa
Anja Federa
PHPetra Heffeter
Petra Heffeter
Human serum albumin (HSA) is a clinically validated drug carrier that improves drug delivery to tumor tissues. However, clinical imaging strategies are lacking to stratify patients who will benefit from HSA-bound drugs. In this study, we site-selectively radiolabeled HSA with zirconium-89 (89Zr), using the octadentate chelator DFO*, to provide an imaging probe with enhanced stability and sufficient half-life to elucidate the long-term (tumoral) albumin homeostasis. [89Zr]Zr-DFO*malHSA demonstrated excellent metabolic stability and high tumor uptake in a longitudinal PET study (72 h p.i.) using a subcutaneous colorectal cancer allograft model (CT26). Preliminary results also showed enhanced enrichment of the PET probe in an intraperitoneally injected CT26 model indicating the role of the EPR effect not only in subcutaneous models. Consequently, [89Zr]Zr-DFO*malHSA is a promising tool to image albumin accumulation in malignant tissues and should be further (pre)clinically developed as a companion diagnostic agent for patient stratification in trials with albumin-binding drugs.